Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Alkermes plc Reports Second Quarter 2023 Financial Results

      This image opens in the lightbox

      News provided by

      Alkermes plc

      26 Jul, 2023, 11:00 GMT

      Share this article

      Share this article


      — Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGA® Product Royalties —

      — Net Sales of Proprietary Products Increased Approximately 21% Year-Over-Year —

      — Prevailed in Janssen Arbitration; Recorded $248.4 Million in Back Royalties and Interest —

      — GAAP Net Income of $237.1 Million and Non-GAAP Net Income of $94.3 Million —

      — Financial Expectations for Full-Year 2023 Reiterated —

      DUBLIN, July 26, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2023.

      "The second quarter clearly demonstrated Alkermes' strong execution against our strategic priorities. We generated double-digit growth of our proprietary commercial products, advanced our development pipeline, and progressed the planned separation of our oncology business," said Richard Pops, Chief Executive Officer of Alkermes. "As we enter the second half of the year, we are well positioned to continue to make meaningful progress across the business and drive shareholder value."

      "Our second quarter results reflect solid execution across our portfolio, highlighted by 21% year-over-year growth of our proprietary commercial products and reinstatement of the long-acting INVEGA product royalties in the U.S.," commented Iain Brown, Chief Financial Officer of Alkermes. "We are in a strong financial position with more than $907 million of cash and total investments and, today, we are reiterating our financial expectations for 2023 that were provided in June following receipt of the favorable final award in our arbitration with Janssen. We continue to expect royalty revenues from Janssen for these long-acting INVEGA products to be incrementally accretive to Alkermes' bottom line in 2023 and beyond, as we continue to manage our business to drive profitability for the benefit of Alkermes' shareholders."

      Quarter Ended June 30, 2023 Financial Results

      Revenues

      - Total revenues for the quarter were $617.4 million, compared to $276.2 million for the same period in the prior year. Total revenues in the second quarter of 2023 included $248.4 million of back royalties and associated interest related to the successful outcome of the company's arbitration with Janssen Pharmaceutica N.V. (Janssen), a subsidiary of Johnson & Johnson.

      - Net sales of proprietary products for the quarter increased approximately 21% to $231.5 million, compared to $190.8 million for the same period in the prior year.

      • Net sales of VIVITROL® were $102.1 million, compared to $96.1 million for the same period in the prior year, representing an increase of approximately 6%.
      • Net sales of ARISTADA®i were $82.4 million, compared to $74.6 million for the same period in the prior year, representing an increase of approximately 10%.
      • Net sales of LYBALVI® were $47.0 million, compared to $20.1 million for the same period in the prior year, representing an increase of approximately 134%.

      - Manufacturing and royalty revenues for the quarter were $385.9 million, compared to $85.3 million for the same period in the prior year.

      • Royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® (the long-acting INVEGA products) for the quarter were $321.2 million, which included $195.4 million and $50.2 million of back royalties and associated interest related to U.S. net sales of these products in 2022 and in the first quarter of 2023, respectively. The company recorded royalty revenues from these products of $26.6 million for the same period in the prior year.
      • Manufacturing and royalty revenues from VUMERITY® for the quarter were $32.3 million, compared to $26.2 million for the same period in the prior year.

      Costs and Expenses

      - Total operating expenses for the quarter were $378.2 million, compared to $310.7 million for the same period in the prior year. The increase was driven primarily by investment in the launch of LYBALVI and expenses associated with the planned separation of the oncology business.

      • Cost of Goods Manufactured and Sold was $63.3 million, compared to $58.4 million for the same period in the prior year.
      • Research and Development (R&D) expenses were $100.8 million, compared to $92.9 million for the same period in the prior year, primarily reflecting acceleration in recruitment for the nemvaleukin alfa (nemvaleukin) clinical studies and investment in the ALKS 2680 phase 1 study.
      • Selling, General and Administrative (SG&A) expenses were $205.3 million, compared to $150.4 million for the same period in the prior year, primarily reflecting increased investment in the direct-to-consumer advertising campaign to support the launch of LYBALVI and certain expenses related to the planned separation of the oncology business.

      Profitability

      - Net income according to generally accepted accounting principles in the U.S. (GAAP) was $237.1 million for the quarter, or a GAAP basic earnings per share of $1.43 and diluted earnings per share of $1.38, based on 166.3 million and 171.6 million shares outstanding, respectively. This compared to GAAP net loss of $30.1 million, or a basic and diluted GAAP loss per share of $0.18, for the same period in the prior year.

      - Non-GAAP net income was $94.3 million for the quarter, or a non-GAAP basic earnings per share of $0.57 and diluted earnings per share of $0.55, based on 166.3 million and 171.6 million shares outstanding, respectively. Non-GAAP net income excluded back royalties and associated interest paid in the quarter of approximately $197.1 million related to 2022 U.S. net sales of the long-acting INVEGA products and CABENUVA®. This compared to non-GAAP net income of $10.5 million, or a non-GAAP basic and diluted earnings per share of $0.06 for the same period in the prior year.

      Balance Sheet

      - At June 30, 2023, the company recorded cash, cash equivalents and total investments of $907.2 million, compared to $692.5 million at March 31, 2023. The company's total debt outstanding as of June 30, 2023 was $292.0 million.

      Financial Expectations for 2023

      Alkermes reiterated its financial expectations for 2023, as set forth in its press release dated June 6, 2023.

      Separation of Oncology Business

      Alkermes continues to make meaningful progress on the previously announced planned separation of its oncology business into a new, independent publicly-traded company. The separation would allow Alkermes to maintain its focus on researching, developing and commercializing therapies for people living with complex neurological conditions and is expected to accelerate and enhance the profitability of the remaining neuroscience business.

      - In June 2023, Alkermes appointed Caroline J. Loew, Ph.D., as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew joined Alkermes in June as a strategic advisor and will transition to CEO of Mural Oncology upon completion of the separation.

      - Alkermes continues to expect to complete the separation in the second half of 2023, subject to various customary conditions, including final approval from Alkermes' board of directors and receipt of a private letter ruling from the IRS and/or a tax opinion from the company's tax advisor.

      Recent Events

      Corporate

      - In June 2023, the company received a final award (the Final Award) from the arbitral tribunal in its arbitration proceedings with Janssen. In connection with the Final Award, the company raised its financial expectations for 2023 by approximately $425 million, reflecting back royalties and associated interest paid related to 2022 U.S. net sales of the long-acting INVEGA products and CABENUVA and anticipated royalty revenues related to 2023 global net sales of these products. Further details regarding the Final Award can be found here.

      - In June 2023, the company announced that at its 2023 annual general meeting of shareholders, the company's shareholders voted to re-elect all seven of Alkermes' director nominees – Emily Peterson Alva, Shane M. Cooke, Richard B. Gaynor, M.D., Cato T. Laurencin, M.D., Ph.D., Brian P. McKeon, Richard F. Pops and Christopher I. Wright, M.D., Ph.D., and approve all other company proposals presented.  

      Neuroscience

      - In May 2023, the company initiated a phase 1b proof-of-concept study of ALKS 2680, the company's orexin 2 receptor agonist, which is in clinical development for the treatment of narcolepsy and other hypersomnia conditions.

      - In May and June 2023, the company presented research related to its psychiatry portfolio at four scientific conferences. The conferences included: Schizophrenia International Research Society (SIRS) Annual Congress, International Society for Bipolar Disorders (ISBD) Annual Conference, American Psychiatric Association (APA) Annual Meeting, and American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. 

      Oncology

      - In June 2023, the company presented trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial for nemvaleukin, the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting.

      Conference Call

      Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.

      About Alkermes plc

      Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

      Non-GAAP Financial Measures

      This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income and non-GAAP basic and diluted earnings per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

      Non-GAAP net income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

      The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income and non-GAAP basic and diluted earnings per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income and non-GAAP basic and diluted earnings per share should not be considered measures of the company's liquidity.

      A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

      Note Regarding Forward-Looking Statements

      Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including its ability to drive profitability and create value for shareholders; the company's expectations regarding the future royalties to be received from Janssen; the company's expectations regarding the timing, structure, anticipated benefits and other impacts of the planned separation of its oncology business; and the therapeutic and commercial potential of the company's products. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not ultimately separate its oncology business during 2023 or at all; unanticipated developments, costs or difficulties that may delay or otherwise negatively affect the planned separation of the company's oncology business; the planned separation may adversely impact the company's ability to attract or retain key personnel; the unfavorable outcome of arbitration or litigation, including so-called "Paragraph IV" litigation and other patent litigation which may lead to competition from generic drug manufacturers, or other disputes related to the company's products or products using the company's proprietary technologies; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company's regulatory approval strategies or components of the company's marketing applications; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2022 and the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

      VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; CABENUVA® is a registered trademark of ViiV Healthcare UK (No.3) Limited; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.

      (tables follow)







      i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.

      Alkermes plc and Subsidiaries

      Selected Financial Information (Unaudited)






      Condensed Consolidated Statements of Operations - GAAP


      Three Months Ended 


      Three Months Ended 

      (In thousands, except per share data)


      June 30, 2023


      June 30, 2022

      Revenues:





      Product sales, net


      $                  231,477


      $                  190,787

      Manufacturing and royalty revenues


      385,913


      85,326

      Research and development revenue


      7


      106

      Total Revenues


      617,397


      276,219

      Expenses:





      Cost of goods manufactured and sold


      63,260


      58,360

      Research and development


      100,788


      92,873

      Selling, general and administrative


      205,258


      150,377

      Amortization of acquired intangible assets


      8,898


      9,066

      Total Expenses


      378,204


      310,676

      Operating Income (Loss)


      239,193


      (34,457)

      Other Income, net:





      Interest income


      6,769


      896

      Interest expense


      (5,684)


      (2,369)

      Other (expense) income, net


      (525)


      1,810

      Change in the fair value of contingent consideration


      —


      870

      Total Other Income, net


      560


      1,207

      Income (Loss) Before Income Taxes


      239,753


      (33,250)

      Income Tax Provision (Benefit) 


      2,688


      (3,114)

      Net Income (Loss) — GAAP


      $                  237,065


      $                  (30,136)






      Earnings (Loss) Per Share:





      GAAP earnings (loss) per share — basic


      $                        1.43


      $                      (0.18)

      GAAP earnings (loss) per share — diluted


      $                        1.38


      $                      (0.18)

      Non-GAAP earnings per share — basic


      $                        0.57


      $                        0.06

      Non-GAAP earnings per share — diluted


      $                        0.55


      $                        0.06






      Weighted Average Number of Ordinary Shares Outstanding:





      Basic  — GAAP and Non-GAAP


      166,279


      163,839

      Diluted — GAAP


      171,553


      163,839

      Diluted — Non-GAAP


      171,553


      168,706






      An itemized reconciliation between net income (loss) on a GAAP basis and non-GAAP net income is as follows:

      Net Income (Loss) — GAAP


      $                  237,065


      $                  (30,136)

      Adjustments:





      Share-based compensation expense


      28,504


      23,377

      Depreciation expense


      10,114


      10,326

      Amortization expense


      8,898


      9,066

      Final award in the Janssen arbitration (2022 back royalties and interest)


      (197,092)


      —

      Separation expense


      5,857


      —

      Income tax effect related to reconciling items


      816


      (1,383)

      Non-cash net interest expense


      115


      117

      Change in the fair value of contingent consideration and other related assets


      —


      (870)

      Non-GAAP Net Income


      $                    94,277


      $                    10,497

      Alkermes plc and Subsidiaries

      Selected Financial Information (Unaudited)






      Condensed Consolidated Statements of Operations - GAAP


      Six Months Ended 


      Six Months Ended 

      (In thousands, except per share data)


      June 30, 2023


      June 30, 2022

      Revenues:





      Product sales, net


      $                  446,204


      $                  362,055

      Manufacturing and royalty revenues


      458,775


      190,496

      License revenue


      —


      2,000

      Research and development revenue


      13


      213

      Total Revenues


      904,992


      554,764

      Expenses:





      Cost of goods manufactured and sold


      121,435


      113,519

      Research and development


      194,425


      188,826

      Selling, general and administrative


      379,735


      295,429

      Amortization of acquired intangible assets


      17,698


      18,032

      Total Expenses


      713,293


      615,806

      Operating Income (Loss)


      191,699


      (61,042)

      Other Income (Expense), net:





        Interest income


      11,735


      1,469

        Interest expense


      (10,972)


      (4,719)

        Other (expense) income, net


      (564)


      4,241

        Change in the fair value of contingent consideration


      —


      (18,197)

      Total Other Income (Expense), net


      199


      (17,206)

      Income (Loss) Before Income Taxes


      191,898


      (78,248)

      Income Tax Benefit


      (3,322)


      (12,209)

      Net Income (Loss) — GAAP


      $                  195,220


      $                  (66,039)






      Earnings (Loss) Per Share:





      GAAP earnings (loss) per share — basic


      $                        1.18


      $                      (0.40)

      GAAP earnings (loss) per share — diluted


      $                        1.14


      $                      (0.40)

      Non-GAAP earnings per share — basic


      $                        0.58


      $                        0.18

      Non-GAAP earnings per share — diluted


      $                        0.57


      $                        0.18






      Weighted Average Number of Ordinary Shares Outstanding:





      Basic — GAAP and Non-GAAP


      165,686


      163,165

      Diluted — GAAP


      170,747


      163,165

      Diluted — Non-GAAP


      170,747


      167,372






      An itemized reconciliation between net income (loss) on a GAAP basis and non-GAAP net income is as follows:

      Net Income (Loss) — GAAP


      $                  195,220


      $                  (66,039)

      Adjustments:





      Share-based compensation expense


      51,147


      41,720

      Depreciation expense


      20,028


      20,557

      Amortization expense


      17,698


      18,032

      Final award in the Janssen arbitration (2022 back royalties and interest)


      (197,092)


      0

      Separation expense


      9,640


      —

      Income tax effect related to reconciling items


      (179)


      (2,576)

      Non-cash net interest expense


      231


      234

      Reduction in the fair value of contingent consideration and other related assets


      —


      18,197

      Non-GAAP Net Income


      $                    96,693


      $                    30,125

      Alkermes plc and Subsidiaries

      Selected Financial Information (Unaudited)






      Condensed Consolidated Balance Sheets


      June 30, 


      December 31, 

      (In thousands)


      2023


      2022

      Cash, cash equivalents and total investments


      $    907,176


      $        740,075

      Receivables


      334,478


      287,967

      Inventory


      189,372


      181,418

      Contract assets


      —


      8,929

      Prepaid expenses and other current assets


      44,452


      43,527

      Property, plant and equipment, net


      323,801


      325,361

      Intangible assets, net and goodwill


      112,855


      130,553

      Deferred tax assets


      153,152


      115,602

      Other assets


      121,898


      130,546

      Total Assets


      $ 2,187,184


      $     1,963,978

      Accounts payable and accrued expenses


      $    465,691


      $        472,204

      Long-term debt — current portion


      3,000


      3,000

      Other current liabilities


      18,494


      22,538

      Long-term debt   


      289,001


      290,270

      Other long-term liabilities


      130,561


      132,213

      Total shareholders' equity


      1,280,437


      1,043,753

      Total Liabilities and Shareholders' Equity


      $ 2,187,184


      $     1,963,978






      Ordinary shares outstanding (in thousands)


      166,498


      164,377






      This selected financial information should be read in conjunction with the consolidated financial statements
      and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the three and six months ended
      June 30, 2023, which the company intends to file in July 2023.

      Alkermes Contacts:
      For Investors: Sandy Coombs    +1 781 609 6377
      For Media:      Katie Joyce        +1 781 249 8927

      Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg 

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.